Closed-loop insulin delivery systems for people with type 1 diabetes and chronic very poor metabolic control: it works and is safe!
Deepchand S, Balla V, Eroukhmanoff J, et al.
Diabetes Technol Ther. Pub. online 13 Nov 2023.
Leggi
Diabetic ketoacidosis (DKA) at diagnosis in youth with type 1 diabetes (T1D) is associated with a higher hemoglobin A1c even with intensive insulin management
Zaharieva DP, Ding V, Addala A, et al.
Diabetes Technol Ther. Pub. online 13 Nov 2023.
Leggi
The cardiovascular effects of novel weight loss therapies
Usman MS, Davies M, Hall ME, et al.
European Heart Journal. 2023;ehad664.
Leggi
Non‐alcoholic fatty liver disease is associated with brain function disruption in type 2 diabetes patients without cognitive impairment
Li X, Zhang W, Bi Y, et al.
Diabetes Obes Metab. Pub. online 14 Nov 2023.
Leggi
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Hankosky ER, Wang H, Neff LM, et al.
Diabetes Obes Metab. Pub. online 6 Nov 2023.
Leggi
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK
Greenwood SA, Young HML, Briggs J, et al.
Lancet Digit Health. 2023:S2589-7500(23)00204-2.
Leggi
Ascertainment of minimal clinically important differences in the diabetes distress scale–17: a secondary analysis of a randomized clinical trial
Banks J, Amspoker AB, Vaughan EM, et al.
JAMA Netw Open. 2023;6(11):e2342950.
Leggi
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study
Lieverse TTGF, Puchades MJ, Mulder UDJ, et al.
Diabetes Obes Metab. Pub. online 5 Nov 2023.
Leggi
Type 2 diabetes and colorectal cancer risk
Lawler T, Walts ZL, Steinwandel M, et al.
JAMA Netw Open. 2023;6(11):e2343333.
Leggi